281 related articles for article (PubMed ID: 31978211)
41. Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss.
Baudino TA; Maclean KH; Brennan J; Parganas E; Yang C; Aslanian A; Lees JA; Sherr CJ; Roussel MF; Cleveland JL
Mol Cell; 2003 Apr; 11(4):905-14. PubMed ID: 12718877
[TBL] [Abstract][Full Text] [Related]
42. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF.
Jacobs JJ; Scheijen B; Voncken JW; Kieboom K; Berns A; van Lohuizen M
Genes Dev; 1999 Oct; 13(20):2678-90. PubMed ID: 10541554
[TBL] [Abstract][Full Text] [Related]
43. Angelica gigas Nakai and Decursin Downregulate Myc Expression to Promote Cell Death in B-cell Lymphoma.
Kim E; Nam J; Chang W; Zulfugarov IS; Okhlopkova ZM; Olennikov D; Chirikova NK; Kim SW
Sci Rep; 2018 Jul; 8(1):10590. PubMed ID: 30002430
[TBL] [Abstract][Full Text] [Related]
44. The c-MYC oncoprotein as a treatment target in cancer and other disorders of cell growth.
Pelengaris S; Khan M
Expert Opin Ther Targets; 2003 Oct; 7(5):623-42. PubMed ID: 14498825
[TBL] [Abstract][Full Text] [Related]
45. Deletion of Mnt leads to disrupted cell cycle control and tumorigenesis.
Hurlin PJ; Zhou ZQ; Toyo-oka K; Ota S; Walker WL; Hirotsune S; Wynshaw-Boris A
EMBO J; 2003 Sep; 22(18):4584-96. PubMed ID: 12970171
[TBL] [Abstract][Full Text] [Related]
46. In a model of immunoglobulin heavy-chain (IGH)/MYC translocation, the Igh 3' regulatory region induces MYC expression at the immature stage of B cell development.
Yan Y; Park SS; Janz S; Eckhardt LA
Genes Chromosomes Cancer; 2007 Oct; 46(10):950-9. PubMed ID: 17639584
[TBL] [Abstract][Full Text] [Related]
47. MIF loss impairs Myc-induced lymphomagenesis.
Talos F; Mena P; Fingerle-Rowson G; Moll U; Petrenko O
Cell Death Differ; 2005 Oct; 12(10):1319-28. PubMed ID: 15947793
[TBL] [Abstract][Full Text] [Related]
48. AID and RAG1 do not contribute to lymphomagenesis in Emu c-myc transgenic mice.
Nepal RM; Zaheen A; Basit W; Li L; Berger SA; Martin A
Oncogene; 2008 Aug; 27(34):4752-6. PubMed ID: 18408759
[TBL] [Abstract][Full Text] [Related]
49. Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways.
Meng X; Carlson NR; Dong J; Zhang Y
Oncogene; 2015 Nov; 34(46):5709-17. PubMed ID: 25823025
[TBL] [Abstract][Full Text] [Related]
50. Deregulated Myc requires MondoA/Mlx for metabolic reprogramming and tumorigenesis.
Carroll PA; Diolaiti D; McFerrin L; Gu H; Djukovic D; Du J; Cheng PF; Anderson S; Ulrich M; Hurley JB; Raftery D; Ayer DE; Eisenman RN
Cancer Cell; 2015 Feb; 27(2):271-85. PubMed ID: 25640402
[TBL] [Abstract][Full Text] [Related]
51. Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma.
Lucas F; Rogers KA; Harrington BK; Pan A; Yu L; Breitbach J; Bundschuh R; Goettl VM; Hing ZA; Kanga P; Mantel R; Sampath D; Smith LL; Wasmuth R; White DK; Yan P; Byrd JC; Lapalombella R; Woyach JA
Clin Cancer Res; 2019 Oct; 25(20):6260-6273. PubMed ID: 31296529
[TBL] [Abstract][Full Text] [Related]
52. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.
Eischen CM; Weber JD; Roussel MF; Sherr CJ; Cleveland JL
Genes Dev; 1999 Oct; 13(20):2658-69. PubMed ID: 10541552
[TBL] [Abstract][Full Text] [Related]
53.
Mathsyaraja H; Freie B; Cheng PF; Babaeva E; Catchpole JT; Janssens D; Henikoff S; Eisenman RN
Genes Dev; 2019 Sep; 33(17-18):1252-1264. PubMed ID: 31395740
[TBL] [Abstract][Full Text] [Related]
54. A p53 defect sensitizes various stages of B cell development to lymphomagenesis in mice carrying an IgH 3' regulatory region-driven c-myc transgene.
Fiancette R; Rouaud P; Vincent-Fabert C; Laffleur B; Magnone V; Cogné M; Denizot Y
J Immunol; 2011 Dec; 187(11):5772-82. PubMed ID: 22039300
[TBL] [Abstract][Full Text] [Related]
55. New Disubstituted Quindoline Derivatives Inhibiting Burkitt's Lymphoma Cell Proliferation by Impeding c-MYC Transcription.
Liu HY; Chen AC; Yin QK; Li Z; Huang SM; Du G; He JH; Zan LP; Wang SK; Xu YH; Tan JH; Ou TM; Li D; Gu LQ; Huang ZS
J Med Chem; 2017 Jul; 60(13):5438-5454. PubMed ID: 28603988
[TBL] [Abstract][Full Text] [Related]
56. The Mad side of the Max network: antagonizing the function of Myc and more.
Rottmann S; Lüscher B
Curr Top Microbiol Immunol; 2006; 302():63-122. PubMed ID: 16620026
[TBL] [Abstract][Full Text] [Related]
57. Ink4c is dispensable for tumor suppression in Myc-induced B-cell lymphomagenesis.
Nilsson LM; Keller UB; Yang C; Nilsson JA; Cleveland JL; Roussel MF
Oncogene; 2007 May; 26(20):2833-9. PubMed ID: 17099725
[TBL] [Abstract][Full Text] [Related]
58. AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-Myc B-cell lymphoma in vivo.
Devlin JR; Hannan KM; Ng PY; Bywater MJ; Shortt J; Cullinane C; McArthur GA; Johnstone RW; Hannan RD; Pearson RB
FEBS J; 2013 Nov; 280(21):5307-16. PubMed ID: 23331925
[TBL] [Abstract][Full Text] [Related]
59. Genomic characterisation of Eμ-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene.
Lefebure M; Tothill RW; Kruse E; Hawkins ED; Shortt J; Matthews GM; Gregory GP; Martin BP; Kelly MJ; Todorovski I; Doyle MA; Lupat R; Li J; Schroeder J; Wall M; Craig S; Poortinga G; Cameron D; Bywater M; Kats L; Gearhart MD; Bardwell VJ; Dickins RA; Hannan RD; Papenfuss AT; Johnstone RW
Nat Commun; 2017 Mar; 8():14581. PubMed ID: 28262675
[TBL] [Abstract][Full Text] [Related]
60. Addiction to Runx1 is partially attenuated by loss of p53 in the Eµ-Myc lymphoma model.
Borland G; Kilbey A; Hay J; Gilroy K; Terry A; Mackay N; Bell M; McDonald A; Mills K; Cameron E; Neil JC
Oncotarget; 2016 Apr; 7(17):22973-87. PubMed ID: 27056890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
